Cravath, Swaine & Moore LLP Logo
  • Practices
  • People
  • Careers
  • News & Insights
  • Practices
  • People
  • Careers
  • News & Insights
  • Our Story
  • The Cravath System
  • Diversity & Inclusion
  • Pro Bono
  • Alumni Journal
  • 200.Cravath

Cravath’s London Office Moves to 100 Cheapside

Read More

News & Insights

Johnson & Johnson Accepts Offer from The Carlyle Group to Acquire Ortho‑Clinical Diagnostics for $4 Billion

April 02, 2014

On March 31, 2014, Johnson & Johnson announced that it has accepted the binding offer from The Carlyle Group, which was received and announced on January 16, 2014, to acquire its Ortho‑Clinical Diagnostics business for approximately US$4 billion, subject to customary adjustments. Cravath represented Johnson & Johnson in connection with this transaction. The transaction is expected to close toward the middle of the year, upon satisfaction of customary closing conditions.

The Cravath team included partner Robert I. Townsend III and associates Alexander Muller and Stephanie L. Alexis on M&A matters and associate Jarrett R. Hoffman on executive compensation and benefits matters. Ryan M. Farha and Mathieu Francon also worked on M&A matters and Matthew J. Bobby also worked on executive compensation and benefits matters.

Related Practices & Industries

  • Corporate
  • Mergers and Acquisitions
  • Executive Compensation and Benefits
  • Healthcare and Life Sciences

People

Photo
Name
Robert I. Townsend III
Title
Corporate
Title
Partner
Email
rtownsend@cravath.com
Phone
+1-212-474-1964
vCard
Download vCard

    Education

    • J.D., 1990, Harvard Law School
      magna cum laude
    • A.B., 1987, Harvard College
      magna cum laude

    Admitted In

    • New York

    Related News & Insights

    Deals & Cases

    March 12, 2025

    Johnson & Johnson’s $5 Billion Registered Notes Offering and Concurrent €4 Billion Notes Offering

    Cravath represented the underwriters in connection with the $5 billion registered notes offering of Johnson & Johnson, the world’s largest, most diversified healthcare products company. Cravath also represented the underwriters in connection with Johnson & Johnson’s concurrent €4 billion notes offering. Proceeds of both offerings will be used to finance the acquisition of Intra‑Cellular Therapies, Inc. by Johnson & Johnson. The transactions closed on February 20, 2025, and February 26, 2025, respectively.

    Cravath Bicentennial

    Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

    Explore

    Cravath, Swaine & Moore LLP Logo
    • CONTACT US
    • OUR STORY
    • ALUMNI PORTAL
    • DISCLAIMERS & NOTICES

    Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.